Antibodies specific to human prostacyclin synthase

Abstract

A DNA-comprising a DNA having a nucleotide sequence encoding the amino acid sequence of human-originated prostacyclin synthase (PGIS) substantially depicted in Sequence No. 12, a vector comprising said DNA, a host cell transformed with said vector and a method for preparing human-originated PGIS comprising culturing said host cell in a medium. A polypeptide having the amino acid sequence of human-originated PGIS substantially depicted in Sequence No. 12 and an antibody having a reactivity with said human-originated PGIS. A pharmaceutical composition comprising said DNA or a vector comprising said DNA. A method for promoting the production of PGI 2 and a method for treating the diseases induced by a low production of PGI 2 , comprising introducing said DNA or a vector comprising said DNA into human or other animals. The present invention clarifies the primary structure of human-originated PGIS and the nucleotide sequence encoding same. The PGIS and its DNA are useful as reagents for the development of therapeutic agents for the cardiovascular diseases induced by the production imbalance between PGI 2 and TXA 2 , and as diagnostics for determining the in vivo tissue expression level-and distribution of PGIS or mRNA thereof. Moreover, they can be used as therapeutic agents for cardiovascular diseases, which introduce PGIS and the like into human or other animals in a lesion-specific manner. The production method of the present invention is useful for the easy and efficient mass production of the human-originated PGIS. The antibody of the present invention is useful for the purification of the human-originated PGIS and immunohistochemical analysis of the cause of a disease.

What is claimed is  
     
         1 . A DNA comprising a DNA having a nucleotide sequence encoding an amino acid sequence of a human-originated prostacyclin synthase substantially depicted in Sequence Listing, Sequence No. 12.  
     
     
         2 . The DNA of  claim 1 , comprising a DNA having a 28th-1527th nucleotide sequence substantially shown in Sequence Listing, Sequence No. 11.  
     
     
         3 . The DNA of  claim 2 , comprising a DNA having a 28th-1527th nucleotide sequence shown in Sequence Listing, Sequence No. 11.  
     
     
         4 . A polypeptide comprising an amino acid sequence of a human-originated prostacyclin synthase substantially shown in Sequence Listing, Sequence No. 12.  
     
     
         5 . The polypeptide of  claim 4 , comprising an amino acid sequence of a human-originated prostacyclin synthase shown in Sequence Listing, Sequence No. 12.  
     
     
         6 . A recombinant vector comprising the DNA of any one of  claims 1  to  3 .  
     
     
         7 . A host cell transformed with the recombinant vector of  claim 6 .  
     
     
         8 . A transformed cell identified by International Deposit No. FERM BP-4653 or FERM BP-4654.  
     
     
         9 . A method for preparing a human-originated prostacyclin synthase, comprising culturing the host cell of  claim 7  in a medium and recovering a human-originated prostacyclin synthase from the obtained culture.  
     
     
         10 . An antibody having a reactivity with a human-originated prostacyclin synthase comprising an amino acid sequence substantially shown in Sequence Listing, Sequence No. 12.  
     
     
         11 . A pharmaceutical composition comprising the DNA of any one of  claims 1  to  3  and a pharmaceutically acceptable carrier.  
     
     
         12 . A pharmaceutical composition comprising the recombinant vector of  claim 6  and a pharmaceutically acceptable carrier.  
     
     
         13 . A pharmaceutical composition for promoting prostaglandin I 2  production, comprising the DNA of any one of  claims 1  to  3  and a pharmaceutically acceptable carrier.  
     
     
         14 . A pharmaceutical composition for promoting prostaglandin I 2  production, comprising the recombinant vector of  claim 6  and a pharmaceutically acceptable carrier.  
     
     
         15 . A pharmaceutical composition for treating a disease induced by a low production of prostaglandin I 2 , comprising the DNA of any one of  claims 1  to  3  and a pharmaceutically acceptable carrier.  
     
     
         16 . A pharmaceutical composition for treating a disease induced by a low production of prostaglandin I 2 , comprising the recombinant vector of  claim 6  and a pharmaceutically acceptable carrier.  
     
     
         17 . A method for promoting prostaglandin I 2  production, comprising introducing the DNA of any one of  claims 1  to  3  into a human or an animal.  
     
     
         18 . A method for promoting prostaglandin I 2  production, comprising introducing the recombinant vector of  claim 6  into a human or an animal.  
     
     
         19 . A method for treating a disease induced by a low production of prostaglandin I 2 , comprising introducing the DNA of any one of  claims 1  to  3  into a human or an animal.  
     
     
         20 . A method for treating a disease induced by a low production of prostaglandin I 2 , comprising introducing the recombinant vector of  claim 6  into a human or an animal.